Babesia microti nucleic acids (B. microti DNA/RNA)

Babesia microti nucleic acid sequences encompass the genomic DNA and various RNA species of the protozoan parasite responsible for human babesiosis. The 18S ribosomal RNA (rRNA) gene is the most frequently utilized sequence for diagnostic purposes due to its high copy number and conserved regions, which allow for sensitive detection via polymerase chain reaction (PCR) or transcription-mediated amplification (TMA) (Source: CDC, 2023). In the context of clinical medicine, these sequences are critical targets for blood donor screening to prevent transfusion-transmitted babesiosis, a significant concern in endemic regions (Source: FDA, 2019). While most current frontline therapies like atovaquone and azithromycin target the parasite's mitochondrial electron transport chain or apicoplast protein synthesis rather than the nucleic acids directly, the sequences remain the gold standard for monitoring treatment efficacy and parasite clearance (Source: PubMed, PMID: 32853380). Understanding the genetic variability within these sequences is also essential for identifying drug-resistant strains, particularly those with mutations in the cytochrome b gene (Source: PubMed, PMID: 26304363).

Other names

Babesia microti genomeB. microti 18S ribosomal RNA geneBabesia microti DNABabesia microti RNA

While standard therapeutic agents for Babesiosis primarily target metabolic enzymes (e.g., cytochrome b) or protein synthesis (ribosomes), nucleic acid sequences serve as the primary target for diagnostic detection via Nucleic Acid Testing (NAT), which utilizes hybridization and amplification to identify the presence of the parasite in blood samples (Source: FDA, 2019).